Author Interviews, JAMA, Karolinski Institute, Pharmacology, Schizophrenia / 09.06.2017
Long-acting Injectable Medications Reduce Relapse and Rehospitalizations in Schizophrenia
MedicalResearch.com Interview with:
[caption id="attachment_35117" align="alignleft" width="200"]
Prof. Tiihonen[/caption]
Jari Tiihonen, MD, PhD
Professor, Department of Clinical Neuroscience
Karolinska Institutet
Stockholm, Sweden
MedicalResearch.com: What are the limitations of existing analyses of the comparative effectiveness of antipsychotics?
Response: It has remained unclear if there are clinically meaningful differences between antipsychotic treatments in relapse prevention of schizophrenia, due to the impossibility of including large unselected patient populations in randomized controlled trials, and due to residual confounding from selection biases in observational studies.
Prof. Tiihonen[/caption]
Jari Tiihonen, MD, PhD
Professor, Department of Clinical Neuroscience
Karolinska Institutet
Stockholm, Sweden
MedicalResearch.com: What are the limitations of existing analyses of the comparative effectiveness of antipsychotics?
Response: It has remained unclear if there are clinically meaningful differences between antipsychotic treatments in relapse prevention of schizophrenia, due to the impossibility of including large unselected patient populations in randomized controlled trials, and due to residual confounding from selection biases in observational studies.


























